Freenome, a biomarker discovery platform, has acquired UK-based immunodiagnostics developer Oncimmune for a total consideration of GBP 13 million (~USD 16.1 million). The acquisition provides Freenome with additional clinical and commercial resources, including a pipeline of autoantibody targets for cancer indications.

Oncimmune specializes in cancer immune profiling and has a commercialized lung blood test called “EarlyCDT Lung,” which is CE-IVD-marked. This test detects elevated levels of autoantibodies in patients in the early stages of lung cancer. It has been used by over 200,000 high-risk individuals and those with indeterminate pulmonary nodules. In addition, Oncimmune possesses an autoantibody platform and a pipeline of over seven cancer detection signatures under development.

Freenome aims to enhance its multiomics platform with non-tumor-derived signals by leveraging Oncimmune's assets. The acquisition strengthens Freenome's screening capabilities for multiple cancers and accelerates the timeline for bringing screening tests to clinical care. The addition of Oncimmune’s expertise and technology complements Freenome's existing efforts in early cancer detection and population health solutions.